Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
/PRNewswire/ BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today.
Eight new companies have joined The BioInnovation Institute’s (BII’s) Venture Lab acceleration program for early-stage companies, it was announced today (August 31).
Embark Laboratories: Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.